Overview

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Status:
Completed

Trial end date:
2016-01-08

Target enrollment:

Participant gender:

Summary

The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same population.

Phase:

Phase 2

Details

Lead Sponsor:

MedImmune LLC

Treatments:

Bendamustine Hydrochloride
Rituximab